Taken together, these results further support our hypothesis that MYDGF serves as a factor involved in the crosstalk between the bone marrow and liver and that MYDGF derived from BMCs protects against NAFLD by decreasing hepatocyte inflammation and lipogenesis. The gene discussed is MYDGF; the disease is metabolic dysfunction-associated steatotic liver disease.